All In Biotech

Drug Trial Radar · NCT07357597

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

A Phase IV, Open-Label, Single-Arm Study of Prophylaxis for Datopotamab Deruxtecan-related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer (TROPION-SWISH)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 24, 2026

Primary completion

Jan 4, 2028

Study completion Jan 4, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jan 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer

Conditions

  • Stomatitis

Interventions

  • Dexamethasone mouthwashDrug

    Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.

  • Datopotamab Deruxtecan (Dato-DXd)Drug

    Commercially available Dato-DXd is prescribed and administered to participants according to standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Dato-DXd treatment-emergent grade ≥ 2 stomatitis in patients receiving prophylactic dexamethasone mouthwash within first 12 weeks of study treatmentTime frame: From date of first dose of study treatment until 12 weeks after date of first dose of study treatment

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona · Withdrawn

  • Research Site

    Hot Springs, Arkansas · Recruiting

  • Research Site

    Little Rock, Arkansas · Recruiting

  • Research Site

    Duarte, California · Not yet recruiting

  • Research Site

    Glendale, California · Recruiting

  • Research Site

    Lakewood, California · Recruiting

  • Research Site

    Long Beach, California · Recruiting

  • Research Site

    Torrance, California · Not yet recruiting

  • Research Site

    Washington D.C., District of Columbia · Withdrawn

  • Research Site

    Coral Springs, Florida · Recruiting

  • Research Site

    Plantation, Florida · Recruiting

  • Research Site

    Athens, Georgia · Recruiting

  • Research Site

    Boise, Idaho · Withdrawn

  • Research Site

    Park Ridge, Illinois · Withdrawn

  • Research Site

    Fort Wayne, Indiana · Recruiting

  • Research Site

    Elizabethtown, Kentucky · Recruiting

  • Research Site

    Lexington, Kentucky · Recruiting

  • Research Site

    Lexington, Kentucky · Not yet recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    New Orleans, Louisiana · Not yet recruiting

  • Research Site

    Frederick, Maryland · Withdrawn

  • Research Site

    Glenn Dale, Maryland · Not yet recruiting

  • Research Site

    Detroit, Michigan · Not yet recruiting

  • Research Site

    Grayling, Michigan · Recruiting

  • Research Site

    Minneapolis, Minnesota · Recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    Reno, Nevada · Withdrawn

  • Research Site

    Lebanon, New Hampshire · Withdrawn

  • Research Site

    East Syracuse, New York · Recruiting

  • Research Site

    Westbury, New York · Not yet recruiting

  • Research Site

    White Plains, New York · Withdrawn

  • Research Site

    Greensboro, North Carolina · Not yet recruiting

  • Research Site

    Wilson, North Carolina · Recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Wynnewood, Pennsylvania · Recruiting

  • Research Site

    West Columbia, South Carolina · Not yet recruiting

  • Research Site

    Knoxville, Tennessee · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Charleston, West Virginia · Withdrawn

  • Research Site

    Morgantown, West Virginia · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.